Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Poly‐ADP‐ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA‐deficient tumors. However, over 40% of BRCA‐deficient patients fail to respond to PARPi. Here, we report that thioparib, a next‐generation PARPi with high affinity against multiple PARPs, including PARP1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li‐Min, Wang, Pingyuan, Chen, Xiao‐Min, Yang, Hui, Song, Shan‐Shan, Song, Zilan, Jia, Li, Chen, Hua‐Dong, Bao, Xu‐Bin, Guo, Ne, Huan, Xia‐Juan, Xi, Yong, Shen, Yan‐Yan, Yang, Xin‐Ying, Su, Yi, Sun, Yi‐Ming, Gao, Ying‐Lei, Chen, Yi, Ding, Jian, Lang, Jing‐Yu, Miao, Ze‐Hong, Zhang, Ao, He, Jin‐Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994488/
https://www.ncbi.nlm.nih.gov/pubmed/36652375
http://dx.doi.org/10.15252/emmm.202216235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994488/
https://www.ncbi.nlm.nih.gov/pubmed/36652375
http://dx.doi.org/10.15252/emmm.202216235

Ejemplares similares